Can apolipoprotein B be used for making decisions on cardiovascular risk prevention in patients with raised triglycerides? [¿Podemos utilizar la apolipoproteína B en la toma de decisiones para la intervención en el riesgo cardiovascular de pacientes con triglicéridos elevados?]
Gomez Gerique J.A.,Hospital Marques de Valdecilla IFIMAV |
Lavin Gomez B.A.,Hospital Marques de Valdecilla IFIMAV |
Esteban Salan M.,Hospital de Cruces |
Fabiani Romero F.,Hospital Virgen Macarena |
And 2 more authors.
Revista del Laboratorio Clinico
Objective: To analyse the predictive value of several approaches to cardiovascular risk prevention: measuring apolipoprotein B concentrations (apoB), estimation of fractionated LDL cholesterol (cLDLf) and non-HDL cholesterol (HDLc), to predict increases in LDL cholesterol. Material and Methods: Cross-sectional multicentre study in which routine samples from 6094 consecutive patients were analysed. In each patient, LDLc was quantified by routine ultracentrifugation technique (LDLu) and apoB concentrations by a standard immunological method. We also estimated the LDLf and non-HDLc. The values obtained were used to analyse the predictive values of unfractionated LDL cholesterol (cLDLu) into three groups according to their triglyceride concentration (<200, between 200 and 400 and 400. mg/dL) and risk groups as defined by the Adult Treatment Panel (ATP) III guidelines (LDL-C> 70, 100, 130 or 160. mg/dL). Results and conclusions: With all the variables analysed we obtained a good positive predictive value, which varied according to the triglyceride concentrations, with the highest values being obtained for apoB with high specificity cut-off points (AE). Calculations with LDLf values underestimate the patient's risk, while those using non-HDLc overestimate it. Conclusion: The Friedewald formula can be used practically without risk in patients with triglycerides below 200. mg/dL. In patients with elevated triglycerides, apoB (AE cut-off points) is recommended as a positive predictor, and non-HDLc as a negative predictor. © 2011 AEBM, AEFA y SEQC. Source
Martinez N.,Hospital Marques de Valdecilla IFIMAV |
Almaraz C.,Hospital Marques de Valdecilla IFIMAV |
Vaque J.P.,Hospital Marques de Valdecilla IFIMAV |
Varela I.,Institute Biomedicina Y Biotecnologia Of Cantabria |
And 24 more authors.
Splenic marginal zone lymphoma (SMZL) is a B-cell neoplasm whose molecular pathogenesis remains fundamentally unexplained, requiring more precise diagnostic markers. Previous molecular studies have revealed 7q loss and mutations of nuclear factor κB (NF-κB), B-cell receptor (BCR) and Notch signalling genes. We performed whole-exome sequencing in a series of SMZL cases. Results confirmed that SMZL is an entity distinct from other low-grade B-cell lymphomas, and identified mutations in multiple genes involved in marginal zone development, and others involved in NF-κB, BCR, chromatin remodelling and the cytoskeleton. © 2014 Macmillan Publishers Limited. Source